TY - JOUR
T1 - Switching elderly chronic psychotic patients to olanzapine
AU - Barak, Yoram
AU - Shamir, Eyal
AU - Mirecki, Ilona
AU - Weizman, Ronit
AU - Aizenberg, Dov
PY - 2004/6
Y1 - 2004/6
N2 - The purpose of this study was to examine whether elderly chronic schizophrenia or schizoaffective disorder patients would clinically improve if switched to olanzapine from previous neuroleptic treatment. Twenty-one hospitalized patients, aged 60-88 yr, with a diagnosis of chronic schizophrenia or schizoaffective disorder who were being treated with typical neuroleptic medication were switched to olanzapine. The Positive and Negative Symptom Scale (PANSS), Geriatric Depression Scale (GDS) and Clinical Global Impression - Severity (CGI-S) Scale were completed while patients were on their previous medication regimen and again 6 months after the last patient had been started on olanzapine. The mean duration of treatment was 289 d (S.D. = 139). Three patients discontinued the medication. Mean end dose of olanzapine was 12.9 mg (S.D. = 5.7). Paired sample t tests were used to test change on PANSS Positive, Negative and Total scales, CGI, GDS and body weight. PANSS (Positive, p = 0.002; Negative, p = 0.003; General, p = 0.003; and Total, p = 0.000) and CGI (p = 0.000) but not the GDS (p = 0.67) demonstrated statistically significant improvement. There was no significant change in body weight (p=0.61). Elderly patients with aggravation of chronic schizophrenia showed improvement after being switched to olanzapine with no weight gain. Clinically meaningful change was observed in positive and negative psychotic symptomatology but not in depressive symptoms.
AB - The purpose of this study was to examine whether elderly chronic schizophrenia or schizoaffective disorder patients would clinically improve if switched to olanzapine from previous neuroleptic treatment. Twenty-one hospitalized patients, aged 60-88 yr, with a diagnosis of chronic schizophrenia or schizoaffective disorder who were being treated with typical neuroleptic medication were switched to olanzapine. The Positive and Negative Symptom Scale (PANSS), Geriatric Depression Scale (GDS) and Clinical Global Impression - Severity (CGI-S) Scale were completed while patients were on their previous medication regimen and again 6 months after the last patient had been started on olanzapine. The mean duration of treatment was 289 d (S.D. = 139). Three patients discontinued the medication. Mean end dose of olanzapine was 12.9 mg (S.D. = 5.7). Paired sample t tests were used to test change on PANSS Positive, Negative and Total scales, CGI, GDS and body weight. PANSS (Positive, p = 0.002; Negative, p = 0.003; General, p = 0.003; and Total, p = 0.000) and CGI (p = 0.000) but not the GDS (p = 0.67) demonstrated statistically significant improvement. There was no significant change in body weight (p=0.61). Elderly patients with aggravation of chronic schizophrenia showed improvement after being switched to olanzapine with no weight gain. Clinically meaningful change was observed in positive and negative psychotic symptomatology but not in depressive symptoms.
KW - Elderly
KW - Olanzapine
KW - Psychosis
KW - Switch
UR - http://www.scopus.com/inward/record.url?scp=3042619843&partnerID=8YFLogxK
U2 - 10.1017/S1461145703004048
DO - 10.1017/S1461145703004048
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:3042619843
SN - 1461-1457
VL - 7
SP - 165
EP - 169
JO - International Journal of Neuropsychopharmacology
JF - International Journal of Neuropsychopharmacology
IS - 2
ER -